Before Lebanon's crisis, 43.6% of new FDA-approved medicines were registered in Lebanon; for those approved from 2020 to 2024 the figure was 0%, which interviewees linked to an informal policy to hold back costly new medicines.
Published as "Extent and causes of the collapse in the registration of innovative medications in Lebanon: A mixed-methods analysis". The authors compared innovative medicines approved by the FDA or the EMA from 2014 to 2024 with their registration in Lebanon, before (2014 to 2019) and after (2020 to 2024) the crisis, and interviewed policymakers, industry leaders and healthcare providers about why registration slowed.
A new cancer medicine approved abroad since 2020 is unlikely to be registered in Lebanon, so patients and doctors depend on older medicines, generics, biosimilars or imports outside the registered market.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/